CARTER-WALLACE TAKING $36.6 MIL. IN FELBATOL CHARGES: NET SALES UP 12% TO $168.1 MIL.; CHIRON BETASERON SALES ARE $61 MIL. YEAR TO DATE; EQUITY INVESTMENT IN WORKS
Carter-Wallace is taking a one-time pre-tax charge of $36.6 mil. in the second quarter (ended Sept. 30) related to its anticonvulsant Felbatol for inventory write-offs, purchase commitments and anticipated product returns, C-W reported Nov. 10.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth